Company intelligence / Profile preview
Shaperon
Seoul, South Koreashaperon.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shaperon is advancing multiple clinical programs, notably with NuGel for atopic dermatitis and NuSepin for sepsis and COVID-19. Its unique inflammasome inhibition mechanism shows promise in reducing inflammation.
- Therapeutic areas
- GastroenterologyEndocrinologyDermatologyOncologyNeurologyInfectious Diseases
- Modalities
- Inflammasome inhibitorsNanobodies (including bispecific and trispecific nanobodies)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Dong-A STDongkook PharmaceuticalKorea Research Institute of Bioscience and Biotechnology
Beyond the preview
Go deeper on Shaperon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shaperon.